Protein Kinases and Drug Design
Register 3 for the price of 2 with the coupon code rcdvb!
This conference is one of two parallel tracks of the Cancer Summit.
To view the summit agenda, click here.

Dear Colleague,

Kinases, key drivers of malignant transformation and major contributors to a variety of other human pathologies, have emerged as some of the most exciting targets in drug discovery. However, with initial well documented success stories came realization that many hurdles lie in the path of successful development of new drugs, targeting kinase signaling.
GTC’s Protein Kinases and Drug Design conference will bring together speakers representing world leading academic centers and pharmaceutical companies to discuss how to overcome the many hurdles and answer exciting key questions such as:

- What are the best approaches to identify key kinases contributing to neurodegenerative diseases and major forms of human cancer from leukemias and breast cancer to malignant gliomas?
- How do different factors, including genetic background, interactions with stroma, “stemness” of the tumor cells contribute to tumor responses to kinase inhibitors?
- What are the best computational, chemical biology and structural biology approaches to de novo kinase drug design, including a “holy grail” of kinase drug discovery - non-ATP competitive inhibitors?
- What is the right balance between inhibitor selectivity and activity?
- Are covalent inhibitors a “no-no” in drug discovery?
- What have we learned from the use of the latest generation of inhibitors, targeting many of the hottest pathways (PI3K, Her2, CDKs, JNK) in pre-clinical models and clinical trials?
- How can we predict pharmacological properties of new kinase inhibitors?

Experts will also share their positive and negative experiences on how predictive preclinical models are with clinical efficacy and toxicology. This conference is one of two parallel tracks of the Cancer Summit - Novel Approaches to Drug Discovery on November 8-9 in Boston, MA.

Sessions of the Protein Kinases and Drug Design conference:

Recent Advances in Drug Design & Development
Selective vs Non-selective Kinases Inhibitors
Recent Advancements in Hit and Target Identification
Novel Oncology Kinases & Inhibitors
Preclinical Models – How Predictive Are They?
Kinase Targets in Pre-clinical and Clinical Trials

To view the agenda,
click here.
To view the speaker list,
click here.

The conference will run parallel with the 2nd Cancer Epigenetics conference, which brings together a balanced mix of leading experts from the industry and academia to collaborate on the latest cutting edge research on novel mechanisms, therapeutics, drug discovery, developments, biomarkers and diagnostics for cancer epigenetics.

Sign up for the summit pass to have access to both tracks of the summit. Or bring a team of 3 for the price of 2 by
Registering with the coupon code rcdvb!

We look forward to seeing you at the conference!

Sincerely,

2012 Protein Kinases Inhibitors and Drug Design Conference Organizing Committee
SPONSORS
MEDIA PARTNERS
What Past Delegates said:

“Fantastic opportunity to see the very latest research in epigenetics drug-discovery.” - Rab Prinjha, VP Head of Epinova DPU, GSK

"The conference was a huge success, bringing together the top-leaders and innovators in the protein kinase field, where new screening technologies and the most late-breaking clinical kinase targeting drugs were disclosed. The group is growing in numbers each year, but still remains quite manageable to allow for one-on-one interactions and networking. This conference has become indispensable for those in the kinase drug discovery field." - Mark Mulvihill, Associate Director of Chemistry, Oncology, OSI Pharmaceuticals

"The meeting provides an excellent snapshot of the up-to-date state of kinase drug discovery with inputs from both academia and industry. It covers all aspects of the field starting from discussion of well established as well as new emerging kinase targets to the novel classes of small molecule inhibitors to new exciting technologies to study kinases. It also provides ample opportunities for networking and establishing new collaborations." - Dr. Alexei Degterev, Assistant Professor, Tufts University

“An excellent meeting with good organization and top quality speakers and attendees from academia and bio-pharmaceutical as well and biotechnology industry.” - Pfizer

Attend All GTC Conferences for One Year for only $3,995 ($1,990 for Acad/Govt).
Click here to sign up!